@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP20327.RAu_FQ8Mz6YKL63bMkEAJTqCCBnR_8uxhZ3Xkei8dP3OQ130_head { this: np:hasAssertion dgn-np:NP20327.RAu_FQ8Mz6YKL63bMkEAJTqCCBnR_8uxhZ3Xkei8dP3OQ130_assertion; np:hasProvenance dgn-np:NP20327.RAu_FQ8Mz6YKL63bMkEAJTqCCBnR_8uxhZ3Xkei8dP3OQ130_provenance; np:hasPublicationInfo dgn-np:NP20327.RAu_FQ8Mz6YKL63bMkEAJTqCCBnR_8uxhZ3Xkei8dP3OQ130_publicationInfo; a np:Nanopublication . dgn-np:NP20327.RAu_FQ8Mz6YKL63bMkEAJTqCCBnR_8uxhZ3Xkei8dP3OQ130_assertion a np:Assertion . dgn-np:NP20327.RAu_FQ8Mz6YKL63bMkEAJTqCCBnR_8uxhZ3Xkei8dP3OQ130_provenance a np:Provenance . dgn-np:NP20327.RAu_FQ8Mz6YKL63bMkEAJTqCCBnR_8uxhZ3Xkei8dP3OQ130_publicationInfo a np:PublicationInfo . } dgn-np:NP20327.RAu_FQ8Mz6YKL63bMkEAJTqCCBnR_8uxhZ3Xkei8dP3OQ130_assertion { miriam-gene:3630 a ncit:C16612 . lld:C0028754 a ncit:C7057 . dgn-gda:DGNff72f5791f208e155da2efee92242f2c sio:SIO_000628 miriam-gene:3630, lld:C0028754; a sio:SIO_001121 . } dgn-np:NP20327.RAu_FQ8Mz6YKL63bMkEAJTqCCBnR_8uxhZ3Xkei8dP3OQ130_provenance { dgn-np:NP20327.RAu_FQ8Mz6YKL63bMkEAJTqCCBnR_8uxhZ3Xkei8dP3OQ130_assertion dcterms:description "[According to a randomized, single blind, cross-over protocol, six healthy subjects, six obese subjects, and six elderly subjects received on 2 different days, with a 1-week interval, placebo or acipimox (250 mg, orally) at 0700 and 1100 h; GHRH [GHRH-(1-44)NH2; 50 micrograms in healthy subjects and in elderly subjects, 100 micrograms in obese subjects] was injected iv at 1300 h, and blood samples for evaluation of plasma FFA, blood glucose, serum insulin (IRI), and serum GH levels were taken from 1200 to 1500 h. Plasma FFA levels were always lower (P < 0.05) after acipimox than after placebo (0.03 +/- 0.01 vs. 0.13 +/- 0.02 g/L in healthy subjects, 0.09 +/- 0.01 vs. 0.27 +/- 0.02 g/L in obese, 0.02 +/- 0.005 vs. 0.17 +/- 0.01 g/L in elderly subjects); serum IRI levels were also lower (P < 0.05) after acipimox than after placebo in the three groups of subjects (16 +/- 3 vs. 30 +/- 5, 120 +/- 30 vs. 181 +/- 32, and 21 +/- 3 vs. 49 +/- 9 pmol/L); both FFA (P < 0.05) and IRI levels (P < 0.05) were higher in obese than in healthy or elderly subjects after placebo and acipimox.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_curated; sio:SIO_000772 miriam-pubmed:8923850; prov:wasDerivedFrom dgn-void:ctd_human-20130708; prov:wasGeneratedBy eco:ECO_0000218 . dgn-void:ctd_human-20130708 pav:importedOn "2013-07-24"^^xsd:date . dgn-void:source_evidence_curated a eco:ECO_0000205; rdfs:comment "Gene-disease associations manually curated."@en; rdfs:label "DisGeNET evidence - CURATED"@en . } dgn-np:NP20327.RAu_FQ8Mz6YKL63bMkEAJTqCCBnR_8uxhZ3Xkei8dP3OQ130_publicationInfo { this: dcterms:created "2014-10-02T12:32:07+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }